Experimental CAR-T therapy targets Hard-to-Treat HER2 cancers
NCT ID NCT07593820
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new type of cell therapy called p95HER2.CAR-TECH2Me for people with advanced HER2-positive breast, gastric, or endometrial cancers that have spread. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. About 15 participants will receive a single infusion after a short course of chemotherapy, and researchers will closely monitor safety and any signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
p95HER2.CAR-TECH2Me cells (a type of immune cell therapy made from the patient's own blood)
What this could lead to
If it works, this could point toward a new treatment option for advanced HER2-positive cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 15 people, focused mainly on safety. The treatment may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Del Mar
NOT_YET_RECRUITINGBarcelona, Catalonia, 08003, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall D Hebron
RECRUITINGBarcelona, Catalonia, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••